Tikute Sanjaykumar, Deshmukh Pratik, Chavan Nutan, Shete Anita, Shinde Pooja, Yadav Pragya, Lavania Mallika
Enteric Viruses Group, ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, Maharashtra, India.
Maximum Containment Laboratory, ICMR-National Institute of Virology, 130, MCC, 1, Pashan-Sus Rd, Pashan, Pune 411021, Maharashtra, India.
Microorganisms. 2024 Feb 28;12(3):490. doi: 10.3390/microorganisms12030490.
Coxsackievirus-A6 (CV-A6) is responsible for more severe dermatological manifestations compared to other enteroviruses such as CV-A10, CV-A16, and EV-A71, causing HFMD in children and adults. Between 2005 and 2007, the recombinant subclade D3/RF-A started to expand globally, and a CV-A6 pandemic started. The study aimed to conduct whole-genome sequencing (WGS) of an isolated CV-A6 strain from currently circulating HFMD cases from India in 2022. Gene-specific RT-PCR and sequencing were used to perform molecular characterization of the isolated virus. Confirmation of these isolates was also performed by transmission electron microscopy and WGS. Among eleven positive clinical enterovirus specimens, eight CV-A6 strains were successfully isolated in the RD cell line. Isolates confirmed the presence of the CV-A6 strain based on VP1 and VP2 gene-specific RT-PCR. Sequences of isolates were clustered and identified as the novel CV-A6 strain of the D3/Y sub-genotype in India. The studies revealed that the D3/Y sub-genotype is being introduced into Indian circulation. The predicted putative functional loops found in VP1 of CV-A6 showed that the nucleotide sequences of the amino acid were a remarkably conserved loop prediction compatible with neutralizing linear epitopes. Therefore, this strain represents a potential candidate for vaccine development and antiviral studies.
与其他肠道病毒如柯萨奇病毒A10(CV-A10)、柯萨奇病毒A16(CV-A16)和肠道病毒A71(EV-A71)相比,柯萨奇病毒A6(CV-A6)会导致更严重的皮肤表现,可引起儿童和成人手足口病。2005年至2007年间,重组亚分支D3/RF-A开始在全球范围内传播,一场CV-A6大流行由此开始。本研究旨在对2022年从印度当前流行的手足口病病例中分离出的一株CV-A6毒株进行全基因组测序(WGS)。采用基因特异性逆转录聚合酶链反应(RT-PCR)和测序对分离出的病毒进行分子特征分析。还通过透射电子显微镜和WGS对这些分离株进行了确认。在11份临床肠道病毒阳性标本中,有8株CV-A6毒株在人横纹肌瘤细胞系(RD细胞系)中成功分离。基于VP1和VP2基因特异性RT-PCR,分离株证实了CV-A6毒株的存在。分离株的序列聚类后被鉴定为印度D3/Y亚基因型的新型CV-A6毒株。研究表明,D3/Y亚基因型正在引入印度的病毒传播中。在CV-A6的VP1中发现的预测推定功能环表明,氨基酸的核苷酸序列是一个与中和线性表位兼容的高度保守的环预测。因此,该毒株是疫苗开发和抗病毒研究的潜在候选毒株。